Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2011

View Archived Issues

Four-marker signature exhibits improved prognostic accuracy in prostate cancer progression

Azacitidine has dual mechanism of action in resistant cancer cells

PTC Therapeutics achieves first milestone in BMI-1 collaboration with Wellcome Trust

BioDelivery Sciences announces results of FDA meeting on BEMA-delivered buprenorphine/naloxone

Novel HCV NS3/NS4A inhibitors patented by Idenix

Novel IAP inhibitors for treatment of cancer designed at Takeda

Servier presents new anticancer dihydroindolone analogues

Infinity Pharma's IPI-926 enters phase II trial and receives FDA orphan status in chondrosarcoma

Noscira presents new inhibitors of beta-secretase 1 and Abeta production

Kissei claims new catechol O-methyltransferase inhibitors

French scientists present new CK II inhibitors

FDA clears Palatin Technologies' IND for phase IIa PL-3994 trial in asthma

Cempra Pharma provides pipeline update on solithromycin and Taksta

InterMune receives approval for Esbriet in Europe

Endo Pharma launches Fortesta testosterone gel in U.S.

Novel TGFR-2-based trap T22d35 reduces tumor growth in vivo

ACT Biotech files SPA with FDA for phase III telatinib trial

Lycera and Merck & Co. enter into autoimmune treatment collaboration

AGS-004 delays rebound of HIV during interruption of antiretroviral therapy

Phase III ORAL Sync trial of Pfizer's tofacitinib meets primary endpoints

FDA approves removal of boxed warning regarding liver injury from Letairis label

European Commission approves Firazyr self-administration label for HAE

Ziopharm grants exclusive license to Solasia for Zinapar in Asia

Vical and EMA reach agreement on endpoints for pivotal phase III trial of TransVax vaccine

MediciNova and Zhejiang Medicine form partnership for MN-221 in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...